BMF-500 — Investigational Agent
FLT3 Inhibitor · Phase 1 · Biomea Fusion
Mechanism of Action
Orally bioavailable covalent (irreversible) inhibitor of FLT3 that targets both FLT3-ITD and FLT3-TKD mutant kinase, aiming for deeper and more durable target suppression than reversible inhibitors.
Investigational Indications
- FLT3-mutated acute myeloid leukemia
- Acute leukemia